Miller Paul D, Kastner Christof, Ramsey Ernest W, Parsons Keith
Surrey and Sussex NHS Trust Hospital, Surrey, United Kingdom.
Urology. 2003 Jun;61(6):1160-4; discussion 1164-5. doi: 10.1016/s0090-4295(03)00337-6.
To evaluate the durability of benefit associated with cooled high-energy thermotherapy (cooled thermotherapy) using the Targis System with data extending to 5 years after treatment.
At three centers in Canada and the United Kingdom, 150 patients with benign prostatic hyperplasia underwent cooled thermotherapy with the Targis System. This was an outpatient procedure performed without general or regional anesthesia. Patients were followed up at 1 and 6 weeks, 3, 6, and 12 months, and yearly to 5 years.
Patients were evaluated at 1, 2, 3, 4, and 5 years after treatment (n = 132, 111, 90, 77, and 59, respectively). At these intervals, the American Urological Association symptom scores improved by 11.7 (57%), 12.1 (58%), 11.5 (53%), 10.1 (47%), and 10.6 (47%) points (P <0.0001 for each), the peak flow rates improved by a mean of 4.0 (57%), 4.0 (56%), 3.4 (48%), 3.3 (47%) and 2.4 (37%) mL/s (P <0.0001 for each), and quality-of-life scores improved by 2.6, 2.6, 2.5, 2.3, and 2.3 points (P <0.0001 for each). At least a 50% improvement in the American Urological Association symptom score was observed in 63% to 68% of patients available for follow-up at years 1, 2, and 3 and 50% and 51% of patients available for follow-up at years 4 and 5, respectively. Four patients required repeated microwave thermotherapy, 27 required subsequent invasive treatments, 1 permanent catheterization, 11 required alpha-blockers, and 1 antiandrogen therapy.
Cooled thermotherapy with the Targis System produces durable improvements in symptoms, quality of life, and flow rates to at least 5 years after treatment.
使用Targis系统评估冷高温热疗（冷疗）相关益处的持久性，数据延伸至治疗后5年。
在加拿大和英国的三个中心，150例良性前列腺增生患者接受了Targis系统的冷疗。这是一项在无需全身或区域麻醉的情况下进行的门诊手术。患者在1周和6周、3个月、6个月、12个月时接受随访，并每年随访直至5年。
在治疗后1年、2年、3年、4年和5年对患者进行评估（分别为n = 132、111、90、77和59）。在这些时间点，美国泌尿外科学会症状评分分别改善了11.7分（57%）、12.1分（58%）、11.5分（53%）、10.1分（47%）和10.6分（47%）（每个时间点P <0.0001），峰值尿流率平均提高了4.0 mL/s（57%）、4.0 mL/s（56%）、3.4 mL/s（48%）、3.3 mL/s（47%）和2.4 mL/s（37%）（每个时间点P <0.0001），生活质量评分分别提高了2.6分、2.6分、2.5分、2.3分和2.3分（每个时间点P <0.0001）。在1年、2年和3年可进行随访的患者中，分别有63%至68%的患者美国泌尿外科学会症状评分至少改善了50%，在4年和5年可进行随访的患者中，分别有50%和51%的患者症状评分至少改善了50%。4例患者需要重复微波热疗，27例患者需要后续侵入性治疗，1例患者需要长期导尿，11例患者需要使用α受体阻滞剂，1例患者需要抗雄激素治疗。
使用Targis系统进行冷疗可使症状、生活质量和尿流率在治疗后至少5年内持续改善。
